ICT 23
Alternative Names: ICT-23Latest Information Update: 28 Aug 2024
At a glance
- Originator ImCheck Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Autoimmune-disorders in France (Parenteral)
- 03 Jul 2020 ICT 23 is available for licensing as of 03 Jul 2020. https://www.imchecktherapeutics.com/
- 03 Jul 2020 Early research in Autoimmune disorders in France (Parenteral) before July 2020 (ImCheck Therapeutics pipeline, July 2020)